{"groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"FG000","title":"Ixabepilone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible-Second primary cancer site"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Ineligible- Wrong cell type"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible-Inadequate pathology"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"STARTED"},{"achievements":[{"comment":"Eligible and treated patients","groupId":"FG000","numSubjects":"34"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 9/7/2010 and closed to accrual on 8/26/2013 (suspended from 3/5/2012 to 9/30/2012)."}